massively parallel sequencing
A comparison for 144 solid tumor samples showed a "high degree of alignment" with FoundationOne CDx and better calling of CNAs than Illumina's TSO 500.
Thermo Fisher Scientific, Boehringer Ingelheim Partner on Companion Dx for Lung Cancer
The firms will develop multiple NGS-based companion diagnostic tests based on the Oncomine Dx Express Test and Oncomine Dx Target Test.
European Commission Orders Illumina to Divest Grail
Illumina will be able to choose the method of divestment, but may need to provide Grail with more than $1 billion in cash to fund operations for several years.
Illumina, Pillar Biosciences Ink Global Distribution Agreement for Cancer Dx Assays
The firms said their distribution deal will facilitate the integration of Pillar's precision oncology assays and Illumina's sequencers.
Illumina, GenoScreen Partner to Comarket Genomic Testing for Multidrug-Resistant TB
The firms will comarket Illumina next-generation sequencing reagents with GenoScreen's Deeplex Myc-TB NGS-based test for antibiotic resistance in TB.
Mar 30, 2021
FTC Moves to Block Illumina's $8B Grail Acquisition
Feb 25, 2021
Feb 24, 2021
Adaptive Biotechnologies Q4 Revenues Rise 25 Percent
Nov 10, 2020